explore -WSS

explore

author：focus 2025-09-27 13:03:57 - browse：66

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： The best solution to the drug shortages problem

focus

WSS

Inaction leaves children at risk from dangerous chemotherapy drug

Immunocompromised patients offer clues on chronic Covid

Flu vaccine reformulation won't be easy, manufacturers warn

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

FDA endorses new sterilization method for medical devices

American woman, child freed after being kidnapped in Haiti last month

leisure time

explore

hotspot

Moonlake's readout produced a cash windfall. Risks remain

CVS is on a mission to consolidate health care. Will it work?

As demand for Covid shots wanes, Moderna seeks its next success

Naloxone nonprofit donates 200,000 doses after FDA approval

Bright Health sells Medicare Advantage business to Molina

Man killed during FBI raid in connection with threats against Biden, other officials

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Tori Bowie and the unacceptable rates of Black maternal death

Dana Farber says 6 studies to be retracted and 31 corrected

focus

A pediatrician calls for Congress to pass the child tax credit deal

To bolster infectious disease surveillance, genomics powerhouses team up

Immunocompromised patients offer clues on chronic Covid

Microsoft launches AI tool for clinical documentation through Epic

Friends ask where James Watson's attitudes about race came from

FDA sets aggressive timeline for overhauling inspection procedures

focus

focus

leisure time

entertainment